PubRank

David H Gutmann

Author PubWeight™ 251.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Subtypes of medulloblastoma have distinct developmental origins. Nature 2010 5.94
2 Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008 5.89
3 Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008 5.55
4 International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002 4.27
5 Neurofibromatosis 2. Curr Opin Neurol 2003 3.46
6 Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol 2002 3.37
7 Neurofibromatosis type 1 revisited. Pediatrics 2009 3.06
8 Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res 2007 3.05
9 Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol 2014 3.01
10 Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007 2.75
11 Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res 2004 2.75
12 Astrocyte-specific inactivation of the neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol 2002 2.65
13 Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 2008 2.65
14 Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 2010 2.56
15 Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 2002 2.39
16 Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 2003 2.30
17 Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 2005 2.02
18 Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell 2007 1.92
19 Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development 2005 1.85
20 Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet 2007 1.80
21 Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006 1.80
22 Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model. Ann Neurol 2003 1.72
23 Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res 2007 1.69
24 Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. Cancer Res 2007 1.65
25 Nectin-like proteins mediate axon Schwann cell interactions along the internode and are essential for myelination. J Cell Biol 2007 1.63
26 Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 2005 1.63
27 Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene 2004 1.61
28 Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci 2002 1.59
29 Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. Brain Pathol 2008 1.59
30 RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 2005 1.55
31 Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet 2010 1.53
32 Predictive value of café au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1. Arch Dermatol 2009 1.52
33 Epileptogenesis and reduced inward rectifier potassium current in tuberous sclerosis complex-1-deficient astrocytes. Epilepsia 2005 1.48
34 Merlin is a potent inhibitor of glioma growth. Cancer Res 2008 1.47
35 Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia 2004 1.47
36 Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res 2008 1.47
37 Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. Glia 2009 1.46
38 Defining future directions in spinal cord tumor research: proceedings from the National Institutes of Health workshop. J Neurosurg Spine 2010 1.45
39 Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. Genes Dev 2010 1.43
40 Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002 1.43
41 Molecular pathogenesis of meningiomas. J Neurooncol 2004 1.42
42 High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res 2006 1.42
43 Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 2008 1.41
44 Visual function and optic pathway glioma: a critical response. JAMA Ophthalmol 2013 1.41
45 Neurofibromatosis 1: from lab bench to clinic. Pediatr Neurol 2005 1.40
46 Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiol Dis 2007 1.37
47 Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A 2010 1.36
48 Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 2002 1.36
49 Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc Natl Acad Sci U S A 2006 1.35
50 Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J Biol Chem 2003 1.35
51 Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A 2004 1.34
52 Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother 2009 1.33
53 Neurofibromatosis type 1 - a model for nervous system tumour formation? Nat Rev Cancer 2005 1.33
54 Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci 2005 1.33
55 Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer 2008 1.33
56 Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. Oncogene 2004 1.32
57 Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivo. Neuroimage 2007 1.32
58 Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat Cell Biol 2007 1.31
59 Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res 2005 1.30
60 Neurofibromatosis 1. Neurol Clin 2002 1.30
61 Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes Dev 2012 1.30
62 Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol 2002 1.29
63 Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A 2003 1.28
64 Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol 2012 1.27
65 The natural history and treatment of epilepsy in a murine model of tuberous sclerosis. Epilepsia 2007 1.26
66 Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol 2013 1.26
67 Innate neural stem cell heterogeneity determines the patterning of glioma formation in children. Cancer Cell 2012 1.26
68 Expression of ICAM-1, TNF-alpha, NF kappa B, and MAP kinase in tubers of the tuberous sclerosis complex. Neurobiol Dis 2003 1.26
69 Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J Neurosci 2010 1.25
70 Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res 2008 1.24
71 The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia 2008 1.23
72 Recent advances in neurofibromatosis type 1. Curr Opin Neurol 2004 1.23
73 Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol 2013 1.22
74 Astrocyte loss of mutant SOD1 delays ALS disease onset and progression in G85R transgenic mice. Hum Mol Genet 2010 1.21
75 The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci 2003 1.21
76 Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth. J Neuropathol Exp Neurol 2011 1.20
77 Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proc Natl Acad Sci U S A 2011 1.20
78 Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res 2003 1.20
79 Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res 2010 1.20
80 Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res 2011 1.20
81 Reduced striatal dopamine underlies the attention system dysfunction in neurofibromatosis-1 mutant mice. Hum Mol Genet 2010 1.18
82 Astrocyte gp130 expression is critical for the control of Toxoplasma encephalitis. J Immunol 2008 1.18
83 Natural history of neurofibromatosis 1-associated optic nerve glioma in mice. Ann Neurol 2005 1.16
84 Meningioma: an update. Curr Opin Neurol 2004 1.16
85 Expression profiling in tuberous sclerosis complex (TSC) knockout mouse astrocytes to characterize human TSC brain pathology. Glia 2004 1.16
86 Deconvoluting mTOR biology. Cell Cycle 2012 1.16
87 T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21(CIP1/WAF1) expression. Mol Cell Biol 2003 1.15
88 Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model. Am J Pathol 2005 1.15
89 Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation. Ann Neurol 2013 1.14
90 Integrin-dependent and -independent functions of astrocytic fibronectin in retinal angiogenesis. Development 2011 1.13
91 Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord. Development 2012 1.13
92 The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res 2010 1.12
93 Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma. Ann Neurol 2014 1.12
94 Astrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculature. PLoS One 2010 1.11
95 Tumorigenesis in the brain: location, location, location. Cancer Res 2007 1.09
96 DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo. Oncogene 2004 1.09
97 The neurobiology of neurooncology. Ann Neurol 2006 1.09
98 BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 2013 1.08
99 TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation. Cancer Res 2007 1.08
100 Neurofibromatosis 1: closing the GAP between mice and men. Curr Opin Genet Dev 2003 1.08
101 Histopathologic predictors of pilocytic astrocytoma event-free survival. Acta Neuropathol 2009 1.08
102 Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma. Int J Cancer 2006 1.07
103 Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells. Oncogene 2002 1.06
104 Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol 2004 1.06
105 Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner. Mol Cell Neurosci 2011 1.02
106 Optic nerve dysfunction in a mouse model of neurofibromatosis-1 optic glioma. J Neuropathol Exp Neurol 2009 1.01
107 Evaluation of participant recruitment methods to a rare disease online registry. Am J Med Genet A 2014 1.01
108 The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol 2008 1.01
109 Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer 2014 1.01
110 Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy. Nat Neurosci 2013 1.01
111 Modeling cognitive dysfunction in neurofibromatosis-1. Trends Neurosci 2013 1.00
112 Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes. J Neuropathol Exp Neurol 2008 1.00
113 Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays. J Neuropathol Exp Neurol 2011 0.98
114 Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer Res 2014 0.98
115 Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. Hum Mol Genet 2002 0.97
116 Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. Ann Neurol 2012 0.97
117 Loss of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced patient survival. J Neuropathol Exp Neurol 2004 0.97
118 CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. Glia 2004 0.97
119 Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology 2013 0.96
120 MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2. Neuro Oncol 2012 0.95
121 Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. Hum Mol Genet 2008 0.94
122 PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. Exp Neurol 2011 0.94
123 Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex. Neurology 2005 0.93
124 Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas. Mod Pathol 2002 0.93
125 Expression profiling identifies a molecular signature of reactive astrocytes stimulated by cyclic AMP or proinflammatory cytokines. Exp Neurol 2007 0.92
126 Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway. Carcinogenesis 2012 0.92
127 Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. J Neurooncol 2012 0.92
128 The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. Am J Med Genet A 2012 0.91
129 Mouse models of tuberous sclerosis complex. J Child Neurol 2004 0.91
130 Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis. Neurobiol Dis 2003 0.91
131 Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. Mol Cancer Ther 2011 0.90
132 Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein. Mol Cell Biol 2005 0.90
133 BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol 2013 0.90
134 ABCA1 influences neuroinflammation and neuronal death. Neurobiol Dis 2013 0.90
135 Novel BRAF Alteration in a Sporadic Pilocytic Astrocytoma. Case Rep Med 2012 0.89
136 The monolayer formation of Bergmann glial cells is regulated by Notch/RBP-J signaling. Dev Biol 2007 0.89
137 Development of an international internet-based neurofibromatosis Type 1 patient registry. Contemp Clin Trials 2012 0.89
138 Diffusion-weighted and dynamic contrast-enhanced imaging as markers of clinical behavior in children with optic pathway glioma. Pediatr Radiol 2008 0.89
139 HRS inhibits EGF receptor signaling in the RT4 rat schwannoma cell line. Biochem Biophys Res Commun 2005 0.88
140 Tuberous sclerosis complex: pathogenesis, diagnosis, strategies, therapies, and future research directions. J Child Neurol 2004 0.88
141 Comparative characterization of the human and mouse third ventricle germinal zones. J Neuropathol Exp Neurol 2011 0.88
142 Generation of a reporter mouse line expressing Akt and EGFP upon Cre-mediated recombination. Genesis 2008 0.88
143 Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. Cancer Res 2006 0.88
144 Meningothelial hyperplasia: a detailed clinicopathologic, immunohistochemical and genetic study of 11 cases. Brain Pathol 2005 0.87
145 F11R is a novel monocyte prognostic biomarker for malignant glioma. PLoS One 2013 0.87
146 Glioneuronal tumours in neurofibromatosis type 1: MRI-pathological study. J Clin Neurosci 2004 0.87
147 The 4.1/ezrin/radixin/moesin domain of the DAL-1/Protein 4.1B tumour suppressor interacts with 14-3-3 proteins. Biochem J 2002 0.87
148 Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet 2002 0.86
149 Fatty acid synthase as a novel target for meningioma therapy. Neuro Oncol 2010 0.86
150 Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression. Oncogene 2005 0.86
151 Postoperative imaging surveillance in pediatric pilocytic astrocytomas. J Neurosurg Pediatr 2010 0.86
152 Epilepsy in individuals with neurofibromatosis type 1. Epilepsia 2013 0.86
153 Alterations of protein 4.1 family members in ependymomas: a study of 84 cases. Mod Pathol 2005 0.86
154 Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. Int J Cancer 2010 0.86
155 Tslc1 (nectin-like molecule-2) is essential for spermatozoa motility and male fertility. J Androl 2006 0.85
156 Akt-dependent cell size regulation by the adhesion molecule on glia occurs independently of phosphatidylinositol 3-kinase and Rheb signaling. Mol Cell Biol 2005 0.85
157 Role of the Rap1 GTPase in astrocyte growth regulation. Glia 2003 0.84
158 Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma. Cancer Res 2005 0.84
159 Attention skills in children with neurofibromatosis type 1. J Child Neurol 2012 0.84
160 Axonal integrity in the absence of functional peroxisomes from projection neurons and astrocytes. Glia 2010 0.84
161 Insights into meningioangiomatosis with and without meningioma: a clinicopathologic and genetic series of 24 cases with review of the literature. Brain Pathol 2005 0.84
162 Brainstem glioma presenting as pruritus in children with neurofibromatosis-1. J Pediatr Hematol Oncol 2009 0.84
163 Functional significance of S6K overexpression in meningioma progression. Ann Neurol 2004 0.83
164 High-fat diet ameliorates neurological deficits caused by defective astrocyte lipid metabolism. FASEB J 2012 0.83
165 Prevalence of Sleep Disturbances in Children With Neurofibromatosis Type 1. J Child Neurol 2013 0.83
166 Conditional KIAA1549:BRAF mice reveal brain region- and cell type-specific effects. Genesis 2013 0.83
167 Identification of transcriptional regulatory networks specific to pilocytic astrocytoma. BMC Med Genomics 2011 0.83
168 Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation. Oncogene 2005 0.83
169 Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium nervous system tumors workshop. Cancer Res 2008 0.82
170 Motivational disturbances and effects of L-dopa administration in neurofibromatosis-1 model mice. PLoS One 2013 0.82
171 The association between hypotonia and brain tumors in children with neurofibromatosis type 1. J Child Neurol 2012 0.82
172 Aberrant G protein signaling in nervous system tumors. J Neurosurg 2002 0.81
173 CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A 2014 0.81
174 Assessment of pain and itch behavior in a mouse model of neurofibromatosis type 1. J Pain 2013 0.81
175 CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. J Neuroimmunol 2010 0.81
176 Reduced T-cadherin expression and promoter methylation are associated with the development and progression of hepatocellular carcinoma. Int J Oncol 2008 0.81
177 Loss of heterozygosity for the NF2 gene in retinal and optic nerve lesions of patients with neurofibromatosis 2. J Pathol 2002 0.81
178 Reduced activity of CD13/aminopeptidase N (APN) in aggressive meningiomas is associated with increased levels of SPARC. Brain Pathol 2009 0.80
179 Diethylstilbestrol effects and lymphomagenesis in Mlh1-deficient mice. Int J Cancer 2005 0.80
180 Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo. Oncogene 2002 0.80
181 Colocalized cellular schwannoma and plexiform neurofibroma in the absence of neurofibromatosis. Case report. J Neurosurg 2007 0.80
182 Expression and function of somatostatin receptors in peripheral nerve sheath tumors. J Neuropathol Exp Neurol 2005 0.79
183 Piebaldism and neurofibromatosis type 1: horses of very different colors. J Invest Dermatol 2004 0.79
184 Developmental delays in children with neurofibromatosis type 1. J Child Neurol 2011 0.79
185 Cancer stem cells and brain tumors: uprooting the bad seeds. Expert Rev Anticancer Ther 2007 0.79
186 Optic nerve tortuosity in children with neurofibromatosis type 1. Pediatr Radiol 2013 0.79
187 Longitudinal analysis of developmental delays in children with neurofibromatosis type 1. J Child Neurol 2012 0.78
188 Genetic heterogeneity of stably transfected cell lines revealed by expression profiling with oligonucleotide microarrays. J Cell Biochem 2003 0.78
189 Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging. Glia 2007 0.78
190 Rap1 activity is elevated in malignant astrocytomas independent of tuberous sclerosis complex-2 gene expression. Int J Oncol 2003 0.78
191 Disruption of 14-3-3 binding does not impair Protein 4.1B growth suppression. Oncogene 2004 0.78
192 Update from the 2013 International Neurofibromatosis Conference. Am J Med Genet A 2014 0.78
193 Parental age and Neurofibromatosis Type 1: a report from the NF1 Patient Registry Initiative. Fam Cancer 2015 0.77
194 Height assessments in children with neurofibromatosis type 1. J Child Neurol 2012 0.77
195 Reply: To PMID 24375753. Ann Neurol 2014 0.77
196 Rethinking pediatric gliomas as developmental brain abnormalities. Curr Top Dev Biol 2011 0.76
197 Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues. Am J Med Genet A 2014 0.76
198 Improving outcomes for neurofibromatosis 1-associated brain tumors. Expert Rev Anticancer Ther 2015 0.76
199 BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Neuro Oncol 2013 0.76
200 All in the family: using inherited cancer syndromes to understand de-regulated cell signaling in brain tumors. J Cell Biochem 2007 0.76
201 Teaching NeuroImages: T2 hyperintensities in neurofibromatosis type 1. Neurology 2013 0.75
202 Neurofibromatosis and other genetic syndromes. Handb Clin Neurol 2012 0.75
203 The 43000 growth-associated protein functions as a negative growth regulator in glioma. Cancer Res 2003 0.75
204 Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions. Expert Rev Neurother 2014 0.75
205 A neuropsychological perspective on attention problems in neurofibromatosis type 1. J Atten Disord 2012 0.75
206 Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. J Neuroophthalmol 2017 0.75